We used routinely collected clinical data from the TB and HIV treatment program in the southern part of Zambia to evaluate effectiveness of cART in reducing mortality among TB-HIV co-infected patients with CD4 + T cells above 350cells/mm3 at the time of TB diagnosis and TB treatment initiation. This evidence concerns the gene CD4 and tuberculosis.